Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
SchaeffersResearch.com21m
Biotech Stock Rises After FDA Approves Non-Opioid Painkiller
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...
healthday34m
FDA Approves First New Non-Opioid Pain Pill in Decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...
FDA approves a new painkiller for the first time in decades
I’m Conway Gittens reporting from the New York Stock Exchange. Here’s what we’re watching on TheStreet today. Wall Street ...
Stocks Climb on Solid Corporate Earnings Results
Real-time index price for KBW Regional Banking Index (KRX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
No Major Catalyst, Wells Fargo Downgraded Vertex
According to the consensus that consist of 29 analysts, the target price for Vertex is ranged from $325.00 to $591.00 with the average of $495.25. GuruFocus estimates the value for Vertex is $434.37, ...